Skip to main content
ISOP ACoP 2025 Annual Conference Main banner

Vivaswath S. Ayyar, PhD (he/him/his)

Scientific Director
GSK, Pennsylvania, United States

Dr. Vivaswath Ayyar is Director, Clinical Pharmacology & Quantitative Medicine, at GSK. An experienced R&D scientist and leader, Dr. Ayyar is dedicated to advancing drug development through innovative, data-driven, and model-informed strategies that enhance decision-making and deliver impactful outcomes for both projects and patients. His current efforts focus on developing and applying mechanism-based PK/PD and modality-centric quantitative systems pharmacology (QSP) models to drive GSK's immunology, hepatology, and infectious disease portfolios. This includes the model-informed development of novel biologics and oligonucleotide therapeutics, particularly small interfering RNAs (siRNAs).

Dr. Ayyar received a Bachelor of Science in Biological Sciences from the University at Buffalo in 2014, followed by a PhD in Pharmaceutical Sciences in 2019, where he worked under the mentorship of Dr. William Jusko. Prior to joining GSK, he spent six years at Johnson & Johnson, where his team established foundational PK-PD concepts and mechanistic models for siRNA therapeutics, now widely used in academia, industry, and regulatory settings to advance oligonucleotide R&D.

In addition to his role at GSK, Dr. Ayyar serves as an Adjunct Assistant Professor of Pharmaceutical Sciences at the University at Buffalo. He has authored over 25 peer-reviewed publications, reviews, and patents.

Disclosure information not submitted.

Presentation(s):